T cell abundance in relation to breast cancer outcomes has been studied thoroughly in White women, in which higher levels of stromal tumor-infiltrating lymphocytes (TILs) are commonly associated with favorable outcomes and therapy response, especially in HER2-positive and triple-negative tumors23–27. This evidence concerns the gene ERBB2 and neoplasm.